AIDS Gel Shown to Protect Anal Tissue From HIV
February 28, 2011
New research presented at the 18th Conference on Retroviruses and Opportunistic Infections (CROI) in Boston, Feb. 27-March 2, shows that a gel containing tenofovir may help prevent HIV when used rectally.
While the tenofovir gel was found to be generally safe, two participants reported severe gastrointestinal side effects, including diarrhea and lower abdominal cramping. In addition, the researchers are reformulating the gel to make it less harmful to the rectum. It is hoped that a formulation that uses less glycerin, an additive common in many gel-like products, will be better tolerated.
Results from a separate, mid-stage study comparing oral and gel forms of tenofovir presented at CROI found daily use of tenofovir gel resulted in a more than 100-times higher concentration of active drug in vaginal tissue compared with the oral drug. However, the daily tablet was associated with a 20-times higher active drug concentration in blood.
That study, led by Dr. Craig Hendrix, a professor of medicine and pharmacology at Johns Hopkins School of Medicine, included U.S. and African women. Most U.S. women in the trial preferred the oral tablet, while African women favored the gel and tablet equally; many reported the gel enhanced sexual pleasure, according to the researchers.
"How the differences between the gel and the tablet will translate in terms of protective effect, we can't say just yet," said Hendrix.
This article was provided by CDC National Prevention Information Network. It is a part of the publication CDC HIV/Hepatitis/STD/TB Prevention News Update.
Add Your Comment:
(Please note: Your name and comment will be public, and may even show up in
Internet search results. Be careful when providing personal information! Before
adding your comment, please read TheBody.com's Comment Policy.)